Caspofungin for Pneumocystis Pneumonia in PLWHIV.
Efficacy of Caspofungin for Pneumocystis Jirovecii Pneumonia in People Living With HIV/AIDS.
Instituto Nacional de Enfermedades Respiratorias
60 participants
Aug 1, 2023
OBSERVATIONAL
Conditions
Summary
Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV/AIDS, often severe and potentially fatal. While trimethoprim/sulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.
Eligibility
Inclusion Criteria4
- Diagnosis of probable or proven PCP, according to its diagnostic classification (refer to classification at the end of this section).
- Have clinical laboratory and virological diagnostic laboratory studies at the time of admission.
- Classification criteria for Pneumonia by P. jirovecii according to Robert-Gangneux et al.:
- Proven: Confirmation by pathology or microbiology. Possible: Presence of three out of four clinical or radiological criteria. Probable: Presence of one clinical or radiological criterion without another identified microorganism.
Exclusion Criteria2
- With a treatment switch to caspofungin after day 7 of treatment initiation (applies only to group B).
- Patients who have developed an additional opportunistic lung infection during their hospitalization, other than cytomegalovirus pneumonitis or SARS-CoV-2 pneumonia.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06691321